Pharmaceuticals

Rising Prevalence Of Chronic Diseases Driving Growth Of The Market Due To Increasing Need For Targeted Treatments And Precision Diagnostics Is Supporting Development Across The Personalized Medicine Biomarkers Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Personalized Medicine Biomarkers Market Through 2030?

The personalized medicine biomarkers market size has shown significant recent growth. It is anticipated to increase from $26.73 billion in 2025 to $31.34 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. The factors contributing to its historical growth include advances in genomic research, a rising incidence of cancer, the expansion of targeted therapies, increased utilization of molecular diagnostics, and regulatory support for precision medicine.

The personalized medicine biomarkers market is projected to experience substantial expansion in the coming years, with its size expected to reach $58.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.0%. This anticipated growth during the forecast period is fueled by several factors, including the increasing use of personalized treatments, a greater need for early disease identification, advancements in pharmacogenomics, increased funding for biomarker research, and broader application in areas beyond oncology. Key trends expected over the forecast period encompass the increasing embrace of precise treatment strategies, the expanded application of biomarkers in cancer care, the deeper incorporation of companion diagnostics, the broader development of predictive and prognostic biomarkers, and a heightened emphasis on tracking treatment effectiveness.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Which Significant Factors Are Encouraging Growth In The Personalized Medicine Biomarkers Market?

An increasing incidence of chronic diseases is anticipated to fuel the expansion of the personalized medicine biomarkers market. These conditions are defined as enduring health issues that evolve gradually, lasting a minimum of one year, necessitating continuous medical care, or restricting daily functions. This rise in chronic diseases stems from factors such as poor lifestyle choices, inadequate nutrition, insufficient exercise, and elevated stress levels. Personalized medicine biomarkers facilitate customized treatments for chronic diseases by pinpointing effective remedies, forecasting disease advancement, and reducing negative reactions, all informed by unique genetic and molecular profiles. For example, data from February 2024, released by the World Health Organization (WHO), a health authority located in Switzerland, projects that new cancer cases will exceed 35 million by 2050, marking a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the increasing occurrence of chronic diseases is a primary catalyst for the expansion of the personalized medicine biomarkers market.

What Segment Types Are Included In The Personalized Medicine Biomarkers Market Analysis?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Which Trends Are Guiding The Development Of The Personalized Medicine Biomarkers Market?

Major companies in the personalized medicine biomarkers market are concentrating on obtaining regulatory approvals, such as companion diagnostic approval, to improve precision oncology by quickly linking patients to appropriate therapies. Companion diagnostic approval refers to the official authorization granted by a health authority (like the FDA) for a diagnostic test specifically designed to determine which patients are most likely to benefit from a particular therapeutic product or face an increased risk of adverse reactions. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test utilizes next-generation sequencing (NGS) technology to detect genetic mutations in cancer cells, allowing clinicians to select the most fitting treatments based on individual biomarkers. This approval signifies a notable progression in precision oncology, aiming to enhance the speed and correctness of treatment selection for cancer patients, ultimately improving personalized care.

Who Are The Key Market Participants In The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Access The Complete Personalized Medicine Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Has The Strongest Presence In The Personalized Medicine Biomarkers Market?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Personalized Medicine Biomarkers Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Personalized Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795